Rhythm Pharmaceuticals (RYTM) Tops Q4 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts RYTM Hot Sheet
Join SI Premium – FREE
Rhythm Pharmaceuticals (NASDAQ: RYTM) reported Q4 EPS of ($0.73), $0.09 better than the analyst estimate of ($0.82). Revenue for the quarter came in at $57.3 million versus the consensus estimate of $55.24 million.
For earnings history and earnings-related data on Rhythm Pharmaceuticals (RYTM) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ardent Health Partners, Inc. (ARDT) Tops Q3 EPS by 8c; offers guidance
- LeMaitre Vascular (LMAT) PT Lowered to $110 at Citizens on Slight EPS, EBITDA Misses
- Sezzle Inc. (SEZL) Reports Q3 EPS of $1.37 ; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
